JP7385658B2 - Cdk9活性を調節するための化合物、組成物、および方法 - Google Patents
Cdk9活性を調節するための化合物、組成物、および方法 Download PDFInfo
- Publication number
- JP7385658B2 JP7385658B2 JP2021521232A JP2021521232A JP7385658B2 JP 7385658 B2 JP7385658 B2 JP 7385658B2 JP 2021521232 A JP2021521232 A JP 2021521232A JP 2021521232 A JP2021521232 A JP 2021521232A JP 7385658 B2 JP7385658 B2 JP 7385658B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- pyrimidin
- reaction mixture
- cdk9
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752635P | 2018-10-30 | 2018-10-30 | |
| US62/752,635 | 2018-10-30 | ||
| US201962884993P | 2019-08-09 | 2019-08-09 | |
| US62/884,993 | 2019-08-09 | ||
| US201962910058P | 2019-10-03 | 2019-10-03 | |
| US62/910,058 | 2019-10-03 | ||
| PCT/US2019/058482 WO2020092314A1 (en) | 2018-10-30 | 2019-10-29 | Compounds, compositions, and methods for modulating cdk9 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505268A JP2022505268A (ja) | 2022-01-14 |
| JP2022505268A5 JP2022505268A5 (cg-RX-API-DMAC7.html) | 2022-10-31 |
| JP7385658B2 true JP7385658B2 (ja) | 2023-11-22 |
Family
ID=70328627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521232A Active JP7385658B2 (ja) | 2018-10-30 | 2019-10-29 | Cdk9活性を調節するための化合物、組成物、および方法 |
Country Status (21)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250174699A (ko) * | 2018-10-30 | 2025-12-12 | 크로노스 바이오, 인코포레이티드 | Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법 |
| US20230158159A1 (en) * | 2020-04-24 | 2023-05-25 | Massachusetts Institute Of Technology | Chimeric degraders of cyclin-dependent kinase 9 and uses thereof |
| WO2022098843A1 (en) * | 2020-11-05 | 2022-05-12 | Kronos Bio, Inc. | Compounds and methods for modulating cdk9 activity |
| AU2022211514B2 (en) * | 2021-01-22 | 2024-06-13 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof |
| EP4436569A4 (en) * | 2021-11-24 | 2025-10-01 | Kronos Bio Inc | POLYMORPHIC AND SALT FORMS OF (LS,3S))-N-(5-(PENTAN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)CYCLOPENTANE-L,3-DIAMINE |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
| WO2024017365A1 (zh) * | 2022-07-22 | 2024-01-25 | 上海海雁医药科技有限公司 | 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用 |
| WO2025153034A1 (zh) * | 2024-01-19 | 2025-07-24 | 上海海雁医药科技有限公司 | 一种吡唑并嘧啶衍生物的磷酸盐多晶型物及其应用 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004087707A1 (en) | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| JP2006502163A (ja) | 2002-09-04 | 2006-01-19 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
| JP2006502184A (ja) | 2002-09-04 | 2006-01-19 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン |
| JP2009511487A (ja) | 2005-10-06 | 2009-03-19 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン |
| JP2010505839A (ja) | 2006-10-04 | 2010-02-25 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターのピラゾロピリミジン |
| JP2010529140A (ja) | 2007-06-05 | 2010-08-26 | エモリー・ユニバーシテイ | サイクリン依存性キナーゼの選択的阻害剤 |
| JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス, インコーポレイテッド | Cdkモジュレーター |
| JP2017506250A (ja) | 2014-02-21 | 2017-03-02 | キャンサー・リサーチ・テクノロジー・リミテッド | Cdk阻害剤としてのピラゾロ[1,5‐a]ピリミジン‐5,7‐ジアミン化合物及びその治療用途 |
| JP2018515434A (ja) | 2015-03-27 | 2018-06-14 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
| EP0714898B1 (en) * | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
| AU747708B2 (en) | 1996-07-24 | 2002-05-23 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| YU23602A (sh) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini |
| PL354675A1 (en) | 1999-09-30 | 2004-02-09 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| JP2002308879A (ja) | 2001-04-13 | 2002-10-23 | Nippon Soda Co Ltd | 5−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤 |
| CA2483306A1 (en) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
| WO2003095455A2 (en) | 2002-05-10 | 2003-11-20 | Smithkline Beecham Corporation | Substituted pyrazolopyrimidines |
| WO2003101993A1 (en) | 2002-06-04 | 2003-12-11 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| GB0305559D0 (en) | 2003-03-11 | 2003-04-16 | Teijin Ltd | Compounds |
| EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| EP1671962A1 (en) | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
| US20070293511A1 (en) | 2003-12-22 | 2007-12-20 | Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation | Crf Receptor Antagonists and Methods |
| US8018479B2 (en) | 2008-08-27 | 2011-09-13 | Lexmark International, Inc. | Method and system for correcting the linearity error in electrophotographic devices |
| CA2576949A1 (en) * | 2004-08-13 | 2006-02-16 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivatives |
| CN101119998A (zh) | 2004-12-21 | 2008-02-06 | 先灵公司 | 吡唑并[1,5-A]嘧啶腺苷A2a受体拮抗剂 |
| DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| EP1931675B1 (en) | 2005-10-06 | 2015-01-14 | Merck Sharp & Dohme Corp. | Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors |
| US20070082900A1 (en) * | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| US8188097B2 (en) | 2005-10-21 | 2012-05-29 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-A]pyrimidine compounds |
| US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| EP2027127A1 (en) | 2006-05-22 | 2009-02-25 | Shering Corporation | Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors |
| CA2691932A1 (en) | 2007-06-27 | 2008-12-31 | Summit Corporation Plc | Use of compounds for preparing anti-tuberculosis agents |
| WO2010074284A1 (ja) | 2008-12-26 | 2010-07-01 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| PL2509602T3 (pl) | 2009-12-04 | 2017-08-31 | Senhwa Biosciences, Inc. | Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 |
| PH12012501643A1 (en) | 2010-02-26 | 2017-07-19 | Mitsubishi Tanabe Pharma Corp | Pyrazolopyrimidine compounds and their use as pde 10 inhibitors |
| WO2011108689A1 (ja) | 2010-03-05 | 2011-09-09 | 協和発酵キリン株式会社 | ピラゾロピリミジン誘導体 |
| CN102958933B (zh) | 2010-06-24 | 2016-02-03 | 吉里德科学公司 | 作为抗病毒药的吡唑并[1,5-a]嘧啶类 |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012044562A2 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
| WO2012170827A2 (en) | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| EP2802588B1 (en) | 2012-01-10 | 2016-05-25 | Bayer Intellectual Property GmbH | Substituted pyrazolopyrimidines as akt kinase inhibitors |
| UA116534C2 (uk) | 2012-02-17 | 2018-04-10 | Мілленніум Фармасьютікалз, Інк. | Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту |
| WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| EP2920181B1 (en) | 2012-11-16 | 2019-01-09 | University Health Network | Pyrazolopyrimidine compounds |
| MX2015011678A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| SG11201507629XA (en) * | 2013-03-15 | 2015-10-29 | Human Biomolecular Res Inst | Compounds and matrices for use in bone growth and repair |
| WO2015153732A2 (en) | 2014-04-01 | 2015-10-08 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
| EP3805218A1 (en) | 2014-04-05 | 2021-04-14 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3268000B1 (en) | 2015-03-09 | 2021-08-04 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| WO2016169995A1 (en) | 2015-04-20 | 2016-10-27 | AbbVie Deutschland GmbH & Co. KG | Substituted pyrazolopyrimidines and method of use |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| ES2767776T3 (es) | 2015-10-01 | 2020-06-18 | Bristol Myers Squibb Co | Inhibidores de biaril cinasa |
| JP2018199623A (ja) | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| WO2017180499A2 (en) | 2016-04-13 | 2017-10-19 | President And Fellows Of Harvard College | Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof |
| WO2019023654A2 (en) * | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF |
| IL317854A (en) | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| KR20250174699A (ko) * | 2018-10-30 | 2025-12-12 | 크로노스 바이오, 인코포레이티드 | Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법 |
-
2019
- 2019-10-29 KR KR1020257039495A patent/KR20250174699A/ko active Pending
- 2019-10-29 BR BR112021008176-3A patent/BR112021008176A2/pt unknown
- 2019-10-29 JP JP2021521232A patent/JP7385658B2/ja active Active
- 2019-10-29 PE PE2021000604A patent/PE20212196A1/es unknown
- 2019-10-29 EP EP19878830.9A patent/EP3873911A4/en not_active Withdrawn
- 2019-10-29 US US16/667,027 patent/US11155560B2/en active Active
- 2019-10-29 CA CA3118472A patent/CA3118472A1/en active Pending
- 2019-10-29 WO PCT/US2019/058482 patent/WO2020092314A1/en not_active Ceased
- 2019-10-29 MD MDA20210033A patent/MD20210033A2/ro not_active Application Discontinuation
- 2019-10-29 MA MA054092A patent/MA54092A/fr unknown
- 2019-10-29 SG SG11202104229WA patent/SG11202104229WA/en unknown
- 2019-10-29 MX MX2021004769A patent/MX2021004769A/es unknown
- 2019-10-29 MY MYPI2021002367A patent/MY210039A/en unknown
- 2019-10-29 CR CR20210202A patent/CR20210202A/es unknown
- 2019-10-29 CN CN201980072853.7A patent/CN112996790B/zh active Active
- 2019-10-29 KR KR1020217016498A patent/KR20210068597A/ko active Pending
- 2019-10-29 EP EP26160798.0A patent/EP4775584A1/en active Pending
- 2019-10-29 AU AU2019370200A patent/AU2019370200B2/en not_active Expired - Fee Related
- 2019-10-29 IL IL282254A patent/IL282254B2/en unknown
-
2021
- 2021-04-14 DO DO2021000066A patent/DOP2021000066A/es unknown
- 2021-04-15 PH PH12021550857A patent/PH12021550857A1/en unknown
- 2021-04-20 ZA ZA2021/02609A patent/ZA202102609B/en unknown
- 2021-04-27 CO CONC2021/0005502A patent/CO2021005502A2/es unknown
- 2021-09-15 US US17/476,237 patent/US11845754B2/en active Active
-
2023
- 2023-11-03 US US18/386,964 patent/US20240132506A1/en not_active Abandoned
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502163A (ja) | 2002-09-04 | 2006-01-19 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
| JP2006502184A (ja) | 2002-09-04 | 2006-01-19 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン |
| WO2004087707A1 (en) | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| JP2009511487A (ja) | 2005-10-06 | 2009-03-19 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン |
| JP2010505839A (ja) | 2006-10-04 | 2010-02-25 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターのピラゾロピリミジン |
| JP2010529140A (ja) | 2007-06-05 | 2010-08-26 | エモリー・ユニバーシテイ | サイクリン依存性キナーゼの選択的阻害剤 |
| JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス, インコーポレイテッド | Cdkモジュレーター |
| JP2017506250A (ja) | 2014-02-21 | 2017-03-02 | キャンサー・リサーチ・テクノロジー・リミテッド | Cdk阻害剤としてのピラゾロ[1,5‐a]ピリミジン‐5,7‐ジアミン化合物及びその治療用途 |
| JP2018515434A (ja) | 2015-03-27 | 2018-06-14 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210068597A (ko) | 2021-06-09 |
| EP4775584A1 (en) | 2026-07-15 |
| MX2021004769A (es) | 2021-08-24 |
| MA54092A (fr) | 2021-09-08 |
| US11155560B2 (en) | 2021-10-26 |
| PE20212196A1 (es) | 2021-11-16 |
| JP2022505268A (ja) | 2022-01-14 |
| US20240132506A1 (en) | 2024-04-25 |
| IL282254B2 (en) | 2025-08-01 |
| DOP2021000066A (es) | 2021-10-31 |
| CA3118472A1 (en) | 2020-05-07 |
| CR20210202A (es) | 2022-02-08 |
| IL282254B1 (en) | 2025-04-01 |
| PH12021550857A1 (en) | 2021-12-06 |
| KR20250174699A (ko) | 2025-12-12 |
| MY210039A (en) | 2025-08-22 |
| US11845754B2 (en) | 2023-12-19 |
| IL282254A (en) | 2021-05-31 |
| AU2019370200A1 (en) | 2021-06-10 |
| CN112996790A (zh) | 2021-06-18 |
| EP3873911A4 (en) | 2022-06-22 |
| BR112021008176A2 (pt) | 2021-08-03 |
| CO2021005502A2 (es) | 2021-09-20 |
| CN112996790B (zh) | 2023-11-03 |
| WO2020092314A1 (en) | 2020-05-07 |
| ZA202102609B (en) | 2023-02-22 |
| AU2019370200B2 (en) | 2024-12-19 |
| US20220002305A1 (en) | 2022-01-06 |
| SG11202104229WA (en) | 2021-05-28 |
| EP3873911A1 (en) | 2021-09-08 |
| US20200131189A1 (en) | 2020-04-30 |
| MD20210033A2 (ro) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112996790B (zh) | 用于调节cdk9活性的化合物、组合物和方法 | |
| KR102824407B1 (ko) | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 | |
| US8653064B2 (en) | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate | |
| CN114867726A (zh) | Kras g12c突变体的小分子抑制剂 | |
| JP2023501399A (ja) | ヘテロ環式rip1阻害化合物 | |
| JP2020528062A (ja) | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 | |
| JP2022546605A (ja) | Rip1阻害化合物ならびにそれを作製および使用するための方法 | |
| CN102171214A (zh) | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
| UA111739C2 (uk) | Імідазопіридазини як інгібітори аkt-кінази | |
| TWI716976B (zh) | 高活性sting蛋白激動劑 | |
| HK1215250A1 (zh) | 氨基取代的异噻唑 | |
| US20180215738A1 (en) | Inhibitors of ack1/tnk2 tyrosine kinase | |
| CN103370321B (zh) | 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途 | |
| WO2023179078A1 (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| OA20540A (en) | Compounds, compositions, and methods for modulating CDK9 activity. | |
| EA043715B1 (ru) | Соединения, композиции и способы модуляции активности cdk9 | |
| TW201910333A (zh) | 哌嗪并雜芳基類衍生物、其製備方法及其在醫藥上的應用 | |
| WO2022257732A1 (zh) | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 | |
| EA047748B1 (ru) | Гетероциклические соединения, ингибирующие rip1 | |
| EA048203B1 (ru) | Соединения, ингибирующие rip1, и способы их получения и применения | |
| HK1146273B (en) | Fused bicyclic pyrimidines | |
| HK1146273A1 (en) | Fused bicyclic pyrimidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221021 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221021 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230522 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231012 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231023 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231110 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7385658 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |